CU6
Clarity Pharmaceuticals Ltd
$2.03
▼ -3.79%
Market cap
$757M
Turnover
$5,216,103
Last price
$2.03
Day change
-3.79%
Announcements
9
Range, past year
Open 3.690 · Low 1.800 · Now 2.030 · High 5.870
Open CU6 in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CU6 momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
18/100
Wyckoff phase
Downtrend27d
Trend stage
Breakdown
1 Day
-3.8%
1 Week
-5.6%
1 Month
-19.1%
1 Year
-46.0%
RSI
37
Avg daily range
6.3%
Clarity Pharmaceuticals Ltd scores 18 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 27 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -29.0%
- High volatility (ATR 6.3%)
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsCU6 announcements
Recent price-sensitive releases.
- 2026-08-27 Preliminary Final Report Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-06 Bioshares Biotech Summit Presentation Company Presentation
- 2026-08-05 SECuRE update Progress Report
- 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-06-29 Data on SAR-bisPSMA to be presented at EANM
- 2026-05-14 Clarity receives $9.8 million R&D tax incentive refund
- 2026-04-30 Quarterly Activities/Appendix 4C Cash Flow Report
More Health Care stocks
Most traded in the same sector.